Age-Old Molecule Offers New Hope for Alzheimer’s

A medical professional holding a brain model in one hand and a yellow supplement capsule in the other

A naturally occurring molecule already in your body might reverse the memory-robbing mechanisms of Alzheimer’s disease, and most people have never heard of it.

Story Snapshot

Calcium alpha-ketoglutarate (CaAKG), a metabolite that declines with age, restored memory and synaptic function in Alzheimer’s disease models
The compound works by repairing early brain damage before severe neurodegeneration, offering a geroprotective approach targeting aging biology
Researchers at National University of Singapore published findings in January 2026 showing CaAKG’s potential as a low-risk intervention
Related bioactives like glucoraphanin from broccoli sprouts preserved cognitive function in a 3.5-year human pilot study with elderly participants
Unlike conventional Alzheimer’s drugs targeting amyloid plaques, these compounds address the root cellular aging processes

The Metabolite Hiding in Plain Sight

Calcium alpha-ketoglutarate exists naturally in every human body, churning through the Krebs cycle to power cellular metabolism. As people age, CaAKG levels plummet, and researchers now believe this decline contributes directly to cognitive deterioration. Professor Brian K. Kennedy and his team at the National University of Singapore tested CaAKG in Alzheimer’s disease models and discovered something remarkable: the compound restored synaptic plasticity, the very foundation of learning and memory that Alzheimer’s destroys. Dr. Sheeja Navakkode, the study’s first author, emphasized the cellular mechanisms at work, showing how CaAKG repaired neuron communication and associative memory through synaptic tagging and capture processes.

Why Targeting Aging Beats Chasing Plaques

The pharmaceutical industry spent decades developing drugs to remove amyloid plaques from Alzheimer’s patients’ brains, with limited success and considerable side effects. CaAKG represents a paradigm shift. Instead of attacking disease symptoms after neurodegeneration begins, it addresses aging biology itself. Kennedy described CaAKG as a “powerful new strategy” precisely because it targets early synaptic deficits before plaques even form. Preclinical studies showed CaAKG supplementation extended lifespan by 10 to 16 percent in models, suggesting its protective effects reach beyond memory into fundamental longevity mechanisms. The safety profile stands out: since the body produces CaAKG naturally, toxicity risks remain minimal compared to synthetic pharmaceuticals.

Broccoli Sprouts Join the Fight

CaAKG is not alone in the emerging bioactive arsenal. A 3.5-year Japanese pilot study tested glucoraphanin, a compound from broccoli sprouts, in elderly people with mild cognitive impairment. The results confirmed long-term cognitive preservation, validating dietary interventions that seemed too simple to work. Sulforaphane, glucoraphanin’s active metabolite, had already shown promise in 12-week elderly trials. Plant-based bioactives such as bacosides from Bacopa monnieri and withanolides from ashwagandha demonstrated neuroprotective effects in rodent Alzheimer’s models throughout the 2000s, inhibiting toxic protein accumulation and activating brain-derived neurotrophic factor. Zeaxanthin, a carotenoid antioxidant, protected against age-related cognitive impairment in earlier studies, rounding out a portfolio of natural compounds targeting dementia through multiple pathways.

The Economic and Social Stakes

Global Alzheimer’s cases approach 50 million and will triple by 2050, creating a healthcare cost crisis exceeding one trillion dollars annually. Nutraceutical interventions like CaAKG and broccoli sprout supplements could slash those costs by delaying disease onset. Singapore’s Healthy Longevity Programme, which funded Kennedy’s research, reflects Asia’s urgent response to rising dementia burdens as populations age rapidly. The nutraceutical market stands to expand dramatically if CaAKG moves from preclinical models to human trials. Longevity biotech companies are already eyeing patent opportunities, while pharmaceutical giants reconsider strategies that ignored endogenous metabolites for decades. The social impact extends beyond economics: empowering people to prevent dementia through accessible compounds restores agency to aging populations tired of waiting for miracle drugs.

From Lab Models to Human Hope

Kennedy and Navakkode’s work remains at the preclinical stage—no human trials for CaAKG in dementia have begun. That gap between laboratory success and clinical application frustrates patients and caregivers searching for immediate solutions. Glucoraphanin advanced further, with human pilot data showing real-world cognitive benefits, but the study’s small scale demands larger randomized controlled trials. The uncertainty around optimal dosing, bioavailability, and long-term safety in diverse populations means years may pass before doctors prescribe CaAKG or broccoli sprout extracts for Alzheimer’s prevention. Kennedy acknowledged that CaAKG should complement, not replace, existing approaches, a pragmatic stance given the complexity of neurodegeneration. Yet the science suggests a credible path forward: targeting the biological aging processes that make brains vulnerable to disease in the first place.